Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan
October 12, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia – – Albireo to receive upfront payment of $15M and...
Albireo Recognizes PFIC Awareness Day 2021
October 05, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource...
Albireo gibt Verfügbarkeit von Bylvay® (Odevixibat) in Deutschland ab sofort bekannt
September 15, 2021 08:30 ET
|
Albireo Pharma, Inc.
– In deutscher Preisliste und allen Apotheken-Softwareprogrammen aufgeführt – – Bylvay ist in den USA, der EU und im Vereinigten Königreich als erste medikamentöse Behandlung für Patienten mit...
Albireo Announces Bylvay® (odevixibat) Now Available in Germany
September 15, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Listed on the German national price list and all pharmacy software programs – – Bylvay is approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2021 16:30 ET
|
Albireo Pharma, Inc.
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement...
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
September 08, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest...
Albireo Sells Priority Review Voucher (PRV) for $105 Million
September 07, 2021 08:30 ET
|
Albireo Pharma, Inc.
– PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat) in July – – Non-dilutive capital further strengthens the Company’s financial position – BOSTON, Sept. 07, 2021 ...
Albireo to Present at Upcoming Investor Conferences
September 02, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper,...
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region
August 18, 2021 01:30 ET
|
Albireo Pharma, Inc.
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC – – PFIC is a life-threatening liver disease and the number one cause of pediatric liver transplants...
Albireo Reports Q2 Financial Results and Business Update
August 05, 2021 08:30 ET
|
Albireo Pharma, Inc.
– BylvayTM (odevixibat) approved in U.S. & EU as only once-daily drug indicated for patients with PFIC – – Commercialization underway with Bylvay, first prescriptions received in the U.S. – –...